Secukinumab

Secukinumab is a human immunoglobulin G1/κ monoclonal antibody targeting interleukin-17A. In clinical trials, 77-81% of the secukinumab patients achieved a PASI75 response in 12 weeks. As well as in chronic plaque psoriasis, secukinumab has also been found effective and safe as monotherapy in nail a...

Full description

Bibliographic Details
Main Author: Nilgün Atakan
Format: Article
Language:English
Published: Galenos Publishing House 2022-04-01
Series:Turkderm Turkish Archives of Dermatology and Venereology
Subjects:
Online Access:https://journal.turkderm.org.tr/jvi.aspx?pdir=turkderm&plng=eng&un=TURKDERM-37929&look4=